FDA approves new Non-Opioid Painkillers Medicine Journal: What to Know

On January 31, 2025By Littum

FDA’s unsubscribe on the medicine is coming as the agency says it prioritizes supporting the development of non-opioid pain management

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medicine that provides an alternative to addictive opioids to patients who want to deal with certain kinds of pain.

The drug, Suzetrigin, received the FDA’s official approval stamp Thursday, which was sold as a 50-MILLRAM prescription pill taken every 12 hours, According to a press release. The medicine will be sold under the branded Journavx for $ 15.50 per day. Pill, according to Vertex Pharmaceuticals, the company that developed the new drug.

The FDA’s unsubscribe on the medicine is coming as the agency says it is prioritizing supporting the development of non-opioid pain management. Suzetrigin is the first non-opioid painkiller or medicine to control pain-of its class to receive federal approval of more than 20 years.

Vertex Pharmaceuticals claimed In a press release That the medicine can be used for many types of moderate to severe acute pain and has shown no evidence that it is addictive, like opioids.

“Today’s approval is an important milestone for public health in acute pain management,” Jacqueline Corrigan-curay, acting director of the FDA Center for Drug Evaluation and Research, said in a statement. “This act and the agency’s designations to accelerate the development and review of the drug emphasize FDA’s obligation to approve secure and effective alternatives to opioids to pain management.”

FDA -Authorization of Journavx comes after 2 drug trials

Journavx was evaluated in two random double -blind experiments with a total of 874 participants after surgical procedures where information was detained from participants who may have affected their behavior or perception.

One of the drug trials followed abdominoplastic operations – known in general as a “stomach -tuck” – while the other followed bunionectomies or an operation on the toes. Both attempts involved randomly administration of placeboos and the active drug, and all participants were able to use ibuprofen if the pain became too great.

“Both attempts demonstrated a statistically significantly superior reduction in pain with Jouravx compared to placebo,” the FDA said in its press release.

How does Jouravx work?

Acute pain is somewhat more than 80 million Americans filling prescriptions for treatment every year, according to Vertex.

Unlike chronic pain that may last well after an injury or illness has been treated, Acute pain is more suddenly – Often caused by surgery or injury – and is easier to treat in the short term.

Journavx was found to help reduce pain by blocking pain signals in the peripheral nervous system before pain signals reach the brain.

Reshma Kewalramani, CEO and President of Vertex, called the drug’s approval “a historic milestone” in a statement.

“We have the opportunity to change the paradigm for acute pain management and establish a new standard for care,” Kewalramani said.

Does Journavx have any known side effects?

The most common reaction study participants who experienced after receiving Journavx were itching, muscle spasms and rashes, according to the FDA.

Eric Lagatta covers breaking and trending news for USA Today. Well him at [email protected]